RecruitingNCT06976606

A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM

An Observational Study to Assess Real-world Patient Characteristics, Clinical Course, and Treatment Patterns for Symptomatic Patients With Arrhythmogenic Cardiomyopathy (ACM) Due To a PlaKoPhilin-2 Pathogenic Variant (PKP2)

Sponsor

Lexeo Therapeutics

Enrollment

40 participants

Start Date

Jan 23, 2024

Study Type

OBSERVATIONAL

Conditions

Arrhythmogenic Cardiomyopathy PKP2-ACM PKP2-ARVC

Summary

An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with arrhythmogenic cardiomyopathy, pkp2-acm, and other related conditions. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.